RxDoctor Payments Data

Ramana Kalli, MD

Cardiovascular Disease · Macon, GANPI 1700951308

Payments from drug & device makers

$1,398in general payments, 2019–2025

Across 63 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$420
  • Merck$170
  • Johnson & Johnson$169
  • Medtronic$114
  • AstraZeneca$83
  • Boehringer Ingelheim$60
  • plus $383 from 12 others

What the payments were for

  • Food & beverage$1,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,398 in reported general payments places this provider in the 35th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$136,260
Medicare patients
429
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$168,708
XareltoRivaroxaban55$48,477
BrilintaTicagrelor31$19,100
EntrestoSacubitril/Valsartan20$15,538
FarxigaDapagliflozin Propanediol12$10,382
Ranolazine ErRanolazine137$8,514
Flecainide Acetate64$4,387
ClopidogrelClopidogrel Bisulfate246$2,906
Isosorbide Mononitrate ErIsosorbide Mononitrate160$2,723
Diltiazem 24hr Er (Cd)Diltiazem Hcl71$2,057
Metoprolol Succinate157$1,752
Atorvastatin Calcium168$1,733
Diltiazem 24hr Er (La)Diltiazem Hcl17$1,517
Potassium Chloride95$1,486
Nitroglycerin PatchNitroglycerin27$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$168,708186 claims
Johnson & JohnsonXarelto$169$48,47755 claims
AstraZenecaBrilinta, Farxiga$83$29,48243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →